An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Transaction summary

Key questions

• What was the mechanics for this transaction?
  The merchantability was conducted nether a Rule 10b5-1 trading program established connected March 13, 2026, which allows firm insiders to acceptable a predetermined docket for selling shares to debar imaginable conflicts regarding worldly non-public information.

• How does the transaction terms comparison to the existent marketplace level?
  Robins sold shares astatine a weighted mean terms of $22.01, portion the banal was priced astatine $21.50 arsenic of the July 6, 2026, marketplace close.

• What is the presumption of the insider's remaining equity position?
  After disposing of the astir 386,000 shares, Robins continues to clasp 1,019,658 shares directly, representing a post-transaction marketplace worth of $21.61 million.

• What has been the stock's caller show trajectory?
  As of the transaction day connected July 2, 2026, Adaptive Biotechnologies Corporation had generated a one-year full instrumentality of 85%.

Company Overview

Company Snapshot

• Adaptive Biotechnologies develops and commercializes an immune medicine level anchored by its immunoSEQ immunosequencing technology, which enables precise diagnosis and attraction of a wide spectrum of diseases done immune profiling and T-cell receptor analysis.

• The institution generates gross done licensing its proprietary immunosequencing level to diagnostic and therapeutic partners, conducting probe collaborations, and offering objective and probe services that leverage its precocious immune profiling capabilities.

• Adaptive Biotechnologies serves pharmaceutical companies, world probe institutions, objective laboratories, and healthcare systems seeking to make personalized immunotherapies and beforehand precision medicine approaches successful oncology and immunological disorders.

Adaptive Biotechnologies is simply a commercial-stage biotechnology institution investing heavy successful probe and development, arsenic evidenced by its TTM nett nonaccomplishment of $49.7 million. The company's competitory vantage lies successful its proprietary immunosequencing platform, which provides unparalleled insights into immune strategy creation and function, positioning it arsenic a captious infrastructure supplier for the emerging tract of immune medicine and personalized therapeutics.